THERAPY DOSSIER · th-2c7c9de97ccb

SCH221510

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30074175 ↗2018Reported benefit

ORLActivation Mediates a Novel ORLReceptor Agonist SCH221510 Analgesia in Neuropathic Pain in Rats.

RatOtherSprague-DawleyMaleIntrathecal3, 10 and 30 microgramTested on day 7 after chronic constriction injury surgery

Model: Chronic constriction injury of the sciatic nerve producing neuropathic pain

Intrathecal SCH221510 dose-dependently reduced thermal and mechanical hypersensitivity after chronic constriction injury. The analgesia was blocked by the ORL1 antagonist and by intrathecal ORL1 siRNA, indicating that it is mediated by spinal ORL1 activation.

Extraction: extract · Supplied extraction confidence: 0.78. Machine-extracted fields require source verification.

Loading the evidence…